77 related articles for article (PubMed ID: 9818037)
1. Prolactinomas in male and female patients: a comparative clinicopathologic study.
Calle-Rodrigue RD; Giannini C; Scheithauer BW; Lloyd RV; Wollan PC; Kovacs KT; Stefaneanu L; Ebright AB; Abboud CF; Davis DH
Mayo Clin Proc; 1998 Nov; 73(11):1046-52. PubMed ID: 9818037
[TBL] [Abstract][Full Text] [Related]
2. Gender-related differences in prolactinomas. A clinicopathological study.
Schaller B
Neuro Endocrinol Lett; 2005 Apr; 26(2):152-9. PubMed ID: 15855888
[TBL] [Abstract][Full Text] [Related]
3. Pathobiology of pituitary adenomas and carcinomas.
Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
[TBL] [Abstract][Full Text] [Related]
4. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
5. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
6. [Prolactinoma in a child showing high MIB-1 labeling index: a case report].
Akamine S; Miyamoto T; Sugiura Y; Takehara S; Hiramatsu H; Nishizawa S; Yokota N
No Shinkei Geka; 2000 Jun; 28(6):547-53. PubMed ID: 10875113
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
Ma W; Ikeda H; Yoshimoto T
Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
[TBL] [Abstract][Full Text] [Related]
8. Increased MIB-1/Ki-67 labeling index as a predictor of an aggressive course in a case of prolactinoma.
Zornitzki T; Knobler H; Nass D; Hadani M; Shimon I
Horm Res; 2004; 61(3):111-6. PubMed ID: 14671387
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up.
Raverot G; Wierinckx A; Dantony E; Auger C; Chapas G; Villeneuve L; Brue T; Figarella-Branger D; Roy P; Jouanneau E; Jan M; Lachuer J; Trouillas J;
J Clin Endocrinol Metab; 2010 Apr; 95(4):1708-16. PubMed ID: 20164287
[TBL] [Abstract][Full Text] [Related]
10. Prolactin levels and gender are associated with tumour behaviour in prolactinomas but Ki-67 index is not.
Cander S; Gül ÖÖ; Ertürk E; Tuncel E; Ersoy C
Endokrynol Pol; 2014; 65(3):210-6. PubMed ID: 24971922
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
12. The expression of AIB1 correlates with cellular proliferation in human prolactinomas.
Carretero J; Blanco EJ; Carretero M; Carretero-Hernández M; García-Barrado MJ; Iglesias-Osma MC; Burks DJ; Font de Mora J
Ann Anat; 2013 May; 195(3):253-9. PubMed ID: 23433587
[TBL] [Abstract][Full Text] [Related]
13. Gender-related differences in prolactin secretion in pituitary prolactinomas.
Nishioka H; Haraoka J; Akada K; Azuma S
Neuroradiology; 2002 May; 44(5):407-10. PubMed ID: 12012125
[TBL] [Abstract][Full Text] [Related]
14. Giant invasive prolactinoma: a case report and review of nine further cases.
Davis JR; Sheppard MC; Heath DA
Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
[TBL] [Abstract][Full Text] [Related]
15. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
[TBL] [Abstract][Full Text] [Related]
16. Management of resistant prolactinomas.
Olafsdottir A; Schlechte J
Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of RCAS1 in human pituitary adenomas.
Umeoka K; Sanno N; Oyama K; Tahara S; Kurotani R; Ikuyama S; Nakashima M; Watanabe T; Osamura RY; Teramoto A
Mod Pathol; 2001 Dec; 14(12):1232-6. PubMed ID: 11743045
[TBL] [Abstract][Full Text] [Related]
18. Growth potential of prolactinomas in men: is it really different from women?
Nishioka H; Haraoka J; Akada K
Surg Neurol; 2003 May; 59(5):386-90; discussion 390-1. PubMed ID: 12765811
[TBL] [Abstract][Full Text] [Related]
19. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
20. Comparative immunohistochemical analysis of estrogen receptor and chromogranin-A reactivity in plurihormonal human prolactinomas.
Talan-Hranilović J; Gnjidić Z; Sajko T; Vizner B; Vrkljan M
Acta Med Croatica; 2000; 54(2):59-63. PubMed ID: 11028110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
